Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside, Third Edition comprehensively investigates key discoveries in the field of bone biology. New aspects of bone cancer biology are treated in new chapters covering exosomes, autophagy, and metabolism. These have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches.�
The Third Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with 40% new material. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials.
Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases. This revision opens the door to myeloma with two short chapters dedicated to this bone-associated disease.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Epidemiology of Bone Cancer
1. Osteoarchaeology: lessons to learn from the past
2. Epidemiology of primary bone tumors and economical aspects of bone metastases
Models of Bone Cancers and Technical Aspects
Animal Models
3. Animal models of bone sarcomas
4. In vivo models used in studies of bone metastaes
5. Zebrafish models for studying bone tumors
Mathematic models and machine learning
6. Use of machine learning in bone cancers
7. Artifical intelligence for bone cancer imaging
Preparation of tissue samples: technical aspects
8. Technical aspects: how do we best prepare bone samples for proper histological analysis?
Bone Microenvironment and Bone Cancer
Bone niche
9. Bone niche and bone metastases
10. Bone: a fertil soil for tumor development
11. Osteomimicry: old concepts and new findings
Dialog between cancer cells and bone cells
12. Role of mesenchymal stem cells in bone cancers, initiation, propagation and metastasis
13. Technical approaches for studying the communications between osteocytes and cancer cells
14. Osteocytes and bone cancers
15. Immune functions of osteoclasts: new insights for bone cancers
16. Immune infiltrate in bone sarcomas
17. Macrophages and pathophysiology of bone cancers
Mediators of cell communications
18. Growth factors, cytokines and pediatric malignant primary bones tumors
19. The role of NFkB in bone cancer
20. TGF-beta and bone cancers: a specific focus
21. Extracellular vesicles, tumor growth and metastatic process
22. Connexin43 and development of primary bone tumors : osteosarcoma and Ewing's sarcoma
23. The role of endocannabinoid system in bone cancer
Metabolism
24. Impact of the microenvironment acidosis on bone cancers
25. Hypoxic niche and bone cancers
26. Metabolism and bone cancers
Bone Tumor Heterogeneity, Plasticity and Biomarkers
Heterogeneity and plasticity
27. EMT process in bone metastasis
28. Cancer stem cells and clonal evolution in bone sarcomas
29. Dormancy in cancer bone metastasis
Biomarkers
30. Bone Remodelling Markers and Bone Cancer
31. Epigenetic Heterogeneity in Primary Bone Cancers
32. miRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors
33. MicroRNAs and bone metastasis: how small RNAs regulate secondary tumour formation and progression in the skeleton
34. Long-non coding RNA and bone sarcoma
35. Liquid biopsy and circulating tumor cells in bone sarcomas: identification of new biomarkers and analysis of the tumor heterogeneity
36. Disseminated tumor cells in bone marrow of cancer patients
II. PRIMARY BONE TUMORS
Biological aspects
37. Cytogenetics of bone sarcomas
38. Genetic aspects of primary bone tumors
39. Markers of bone sarcomas
40. Molecular pathology of osteosarcoma
41. Genomic and proteomic profiling of osteosarcoma
42. Ewing sarcoma family of tumors
43. Molecular aspects of Ewing sarcomas
44. Osteoclast-rich lesions: a clinical and molecular overview
45. Biology of cartilage tumor family
Clinical aspects and Perspectives
Imaging
46. Imaging of bone sarcomas
Therapeutic approaches
47. Current therapeutic approaches of bone sarcomas
48. Surgical approaches of bone sarcomas: Margins and clinical impact
49. Apoptosis and drug resistance in malignant bone tumors: impact on the clinical practices
50. Chondrosarcoma of Bone: Diagnosis and Therapy
51. Radiotherapy and Primary bone tumors
52. New therapeutic advances of bone sarcomas
III. BONE METASTASES
Biological aspects
53. The histopathology of skeletal Metastases
54. Indentification of new therapeutic targets of bone cancers by proteomic strategies
Clinical aspects and Perspectives
Imaging
55. Interventional radiologic techniques in management of bone tumors
56. Diagnosis of bone metastases in urological malignancies an update
Bone pain
57. Mechanisms and management of bone cancer pain
58. Involvement of sympathic nerves in bone mestastasis
59. Pain control with palliative radiotherapy in patients with bone metastases
60. Palliative care of bone metastases
Therapeutic approaches
61. Radiotherapy of bone metastases
62. Cellular and molecular actions of bisphosphonates: therapeutic interest in tumor-associated bone diseases
63. Bone-Targeted agents and skeletal-related events in breast cancer patients with bone metastases
64. Bone metastases current status of bone-targeted treatments
65. Therapies of bone metastases in castration-resistant prostate cancer
66. Therapy with bone-targeting radiopharmaceuticals
67. Therapeutic approaches of bone metastases associated with breast cancer
MYELOMA: A BONE ASSOCIATED DISEASE
68. Biological relationship between bone and myeloma cells
69. Recent therapeutic approaches in myeloma
Authors
Dominique Heymann Professor, Faculty of Medicine, University of Nantes; Head of Pathophysiology of Bone Resorption and Therapy of Primitive Bone Tumors, INSERM, Nantes, France.Dominique Heymann studied cell biology, biochemistry and immunology in INSERM (French NIH) unit 211 at the University of Nantes and received his Ph.D. in 1995. He was appointed Associate Professor in 2001 in the Department of Histology and Embryology. In 2009, he was awarded a personal Chair of Histology and Embryology.
Currently he is the Quality Control Manager of the Tissue Bank and Gene and Cellular Therapy Unit at Nantes Hospital. He heads a laboratory research group (INSERM UMR 957) of 65 people at the Faculty of Medicine, where the pathogenesis of primary bone tumours, and more specifically, the role of bone microenvironment (osteoclasts, mesenchymal stem cells, OPG/RANK/RANKL, IL-6 and MCSF cytokine family) in tumour growth is studied.
In 2006, Dominique Heymann won the Paul Mathieu prize from the National Academy of Medicine for his work entitled "From the osteolytic process associated to primary bone tumors to the development of bi-therapies for osteosarcoma?. He was on the national scientific advisory board of INSERM (2008-2012) and is now Co-Chairman of INSERM scientific commission n?5 ("Physiology and pathophysiology of endocrine, bone, skin and gastrointestinal tissues?). He has authored approximately 180 publications in peer- reviewed journals, more than 300 abstracts and 20 book chapters. He is also Associate Editor of Life Sciences, Academic Editor of PLoS ONE, Editor-in-Chief of the Open Bone Journal and serves on the Editorial Board of Current Medicine Chemistry, European Journal of Pharmacology, and Journal of Bone Oncology.
